Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
THANK-u Plus is an allogeneic CAR-T cell therapy platform developed by CARsgen Therapeutics. It represents an enhanced version of the company's proprietary allogeneic CAR-T technology, designed to address challenges related to NKG2A expression on natural killer (NK) cells. The platform enables the development of off-the-shelf CAR-T therapies that demonstrate sustained expansion and improved antitumor efficacy in the presence of NK cells compared to earlier versions. Therapies developed using the THANK-u Plus platform include BCMA-targeted and dual-targeting CD19/CD20 CAR-T cells, with robust activity against hematologic malignancies such as relapsed/refractory multiple myeloma and plasma cell leukemia[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on THANK-u Plus.